Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments.
Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body's immune response to selectively target cancer.
Werewolf Therapeutics was founded through an initial investment by MPM Capital in 2019. The company is headquartered in Cambridge, Massachusetts.
Werewolf develops novel immuno-stimulatory therapeutics to more precisely and effectively stimulate anti-tumor immune responses to improve safety, efficacy and durability.
Werewolf's proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential.
Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer.
Werewolf Therapeutics is backed by MPM Capital, Longwood Fund, Taiho Ventures, Arkin Bio Ventures and others. The company raised $56M from a Series A financing on Nov 20, 2019.